A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours
Status:
RECRUITING
Trial end date:
2029-12-01
Target enrollment:
Participant gender:
Summary
This study is to assess the safety and tolerability, obtain the recommended phase 2 dose(RP2D)/or Maximum Tolerated Dose (MTD) for LM-2417 as a single agent or in combination with other anti-tumour agents in subjects with advanced solid tumours.